Daan Genomics announced that recently, the company obtained a medical device registration certificate issued by the State Drug Administration. The details are: medical device name: human parainfluenza virus nucleic acid detection kit, registration certificate number: Guozheng 20263401731. It is valid from the date of approval until August 16, 2031. Intended use: This product is used to qualitatively detect human parainfluenza virus RNA in human pharyngeal swabs, including human parainfluenza virus type 1, human parainfluenza virus type II, human parainfluenza virus type III, and human parainfluenza virus type IV. The test results of this kit do not distinguish between parainfluenza virus types. Obtaining the above medical device registration certificate has enriched the company's product portfolio and broadened the application fields of the company's products. Currently, the above products are still in the market development stage, and market demand is uncertain. Investors are invited to pay attention to investment risks.

Daan Genomics announced that recently, the company obtained a medical device registration certificate issued by the State Drug Administration. The details are: medical device name: human parainfluenza virus nucleic acid detection kit, registration certificate number: Guozheng 20263401731. It is valid from the date of approval until August 16, 2031. Intended use: This product is used to qualitatively detect human parainfluenza virus RNA in human pharyngeal swabs, including human parainfluenza virus type 1, human parainfluenza virus type II, human parainfluenza virus type III, and human parainfluenza virus type IV. The test results of this kit do not distinguish between parainfluenza virus types. Obtaining the above medical device registration certificate has enriched the company's product portfolio and broadened the application fields of the company's products. Currently, the above products are still in the market development stage, and market demand is uncertain. Investors are invited to pay attention to investment risks.